EPISODE · Sep 16, 2025 · 3 MIN
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
from AudioAbstracts
Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
What this episode covers
Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
NOW PLAYING
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.